Picture [LSA] – The Business Web Portal 650x89px
Organisation › Details

Autolus Therapeutics plc (Nasdaq: AUTL)

Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology. Autolus’ shareholders include Syncona LLP, UCL Business PLC, Woodford Investment Management LLP and Perceptive Bioscience Investments Ltd. *


Period Start 2018-06-22 renamed
  Predecessor Autolus Therapeutics Ltd.
Products Industry BIOTECH
  Industry 2 T cell therapy
Persons Person Itin, Christian (Autolus 201603– CEO before Cytos 201211–201601 + Micromet 1999–2012 CEO + Co-founder + Zyomyx Inc)
  Person 2 Oakley, Andrew J. (Autolus 201806– CFO before Sosei + Vectura + Novimmune + Actelion)
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 58 Wood Lane
White City, Forest House
  City W12 7RP London
  Tel +44-20-3829-6230
    Address record changed: 2018-06-28
Basic data Employees n. a.
    * Document for �About Section�: Autolus Therapeutics Ltd.. (3/3/16). "Press Release: Autolus Limited Secures £40 Million Funding – Woodford Investment Management and Perceptive Bioscience Complete Series B Financing". London.
Record changed: 2019-09-17


Picture [LSA] – The Business Web Portal 650x89px

More documents for Autolus Therapeutics plc (Nasdaq: AUTL)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top